Fate of Patients with Adenocarcinoma of the Esophagus and the Esophagogastric Junction: A Population-Based Analysis

Sihvo, Eero I.T.; Luostarinen, Markku E; Salo, Jarmo A
March 2004
American Journal of Gastroenterology;Mar2004, Vol. 99 Issue 3, p419
Academic Journal
OBJECTIVE: At the population level, a detailed picture of the nature of adenocarcinoma at the distal esophagus and esophagogastric junction under modern treatment is lacking. We evaluated the fate of these patients and the results of various types of therapeutic procedures using unselected population-based data.METHODS: Primary data on patients with these adenocarcinomas in two health care districts in Finland were retrieved from the Finnish Cancer Registry. The fate of all 402 patients treated between 1990 and 1998 in 23 units was analyzed.RESULTS: The 5-yr survival rate of these patients was 12.5%. Median survival was 36.5 days (0 days– 68.1 months) with best supportive care (18.9%), 116.5 days (0 days–59.5 months) with palliative (33.8%), mainly either endoscopic or oncological treatment, 211 days (113 days–26.6 months) with exploratory surgery (4.7%), and 17.6 months (0–101.1) after esophageal resection (42.5%). The 5-yr and 8-yr survival rates in this unselected material after esophageal resection including 8.8% operative mortality were 29.0% and 26.0%. The best chance for cure and long-term survival came from esophagectomy with 2-field lymphadenectomy compared to less extensive operations (50.0%vs23.2% survival at 5 yrs,p= 0.005). Between these groups no statistically significant difference (p= 0.4) existed in pathological TNM stages or in the distribution of node-negative tumors (47.6%vs41.8%).CONCLUSIONS: Although overall prognosis for adenocarcinoma near the esophagogastric junction is poor, a substantial percentage of patients eligible for major surgery achieve long-term survival.


Related Articles

  • Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers. Wainberg, Zev; Soares, Heloisa; Patel, Ravi; DiCarlo, Brian; Park, David; Liem, Andre; Wang, He-jing; Yonemoto, Lisa; Martinez, Diego; Laux, Isett; Brennan, Meghan; Hecht, J. // Cancer Chemotherapy & Pharmacology;Jul2015, Vol. 76 Issue 1, p61 

    Purpose: Our study was designed to evaluate the efficacy and safety of everolimus in patients with pre-treated metastatic gastric and esophagus cancers in a US-based population focusing on biomarker correlation. Methods: Patients with advanced upper GI adenocarcinomas who progressed after 1-2...

  • Cost-Effective Screening and Surveillance for Barrett Esophagus Are Limited to Patients with Dysplasia. Dysplasia Inadomi, J. M.; Sampliner, R.; Lagergren, J. // Annals of Internal Medicine;9/7/2004, Vol. 141 Issue 5, p374 

    This article presents information on various gastroenterologic diseases. Although one-time screening endoscopy for Barrett esophagus is recommended for patients with gastroesophageal reflux disease (GERD), little evidence exists about the cost effectiveness of this practice. With as much as 10%...

  • Significance of Macrophage Chemoattractant Protein-1 Expression and Macrophage Infiltration in Squamous Cell Carcinoma of the Esophagusa. Koide, Naohiko; Nishio, Akihito; Sato, Toshiyuki; Sugiyama, Atsushi; Miyagawa, Shin-ichi // American Journal of Gastroenterology;Sep2004, Vol. 99 Issue 9, p1667 

    OBJECTIVES: Macrophage chemoattractant protein-1 (MCP-1) is a chemokine-inducing infiltration of macrophages, which can play several roles in tumor growth and metastasis. We have attempted to clarify the relationship between MCP-1 expression and macrophage infiltration in esophageal squamous...

  • Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus. Wang, Kenneth K.; Sampliner, Richard E. // American Journal of Gastroenterology;Mar2008, Vol. 103 Issue 3, p788 

    The article provides information on the revision made on the 2008 Guidelines for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus. The guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus were originally published by the American College of Gastroenterology...

  • An Unusual Presentation of Metastatic Esophageal Adenocarcinoma Presenting as Thigh Pain. Norris, William E.; Perry, Joseph L.; Moawad, Fouad J.; Horwhat, J. David // Journal of Gastrointestinal & Liver Diseases;Sep2009, Vol. 18 Issue 3, p371 

    The association between esophageal adenocarcinoma and distant skeletal muscle metastasis is extremely rare. Only three cases have been previously reported in the literature. All reported involvement of the gastroesophageal junction. We describe a 58 year-old Caucasian man who presented with...

  • Total and subtotal laparoscopic gastrectomy for adenocarcinoma. Pugliese, R.; Maggioni, D.; Sansonna, F.; Scandroglio, I.; Ferrari, G. C.; Di Lernia, S.; Costanzi, A.; Pauna, J.; de Martini, P. // Surgical Endoscopy;Jan2007, Vol. 21 Issue 1, p21 

    Background: Laparoscopic gastrectomies are currently performed in many centers, but compliance with oncologic requirements still represents a subject open to debate. The aim of this work was to compare the short-term and oncologic outcomes after laparoscopic and open surgery in...

  • Adenocarcinoma appearing very late after antireflux surgery for Barrett's esophagus: long-term follow-up, review of the literature, and addition of six patients Csendes, Attila; Burdiles, Patricio; Braghetto, Italo; Korn, Owen // Journal of Gastrointestinal Surgery;May2004, Vol. 8 Issue 4, p434 

    Antireflux surgery is supposed to prevent the development of adenocarcinoma in patients with Barrett''s esophagus. The purpose of this study was to determine the prevalence of adenocarcinoma late after antireflux surgery. A total of 161 patients with long-segment Barrett''s esophagus had...

  • Management of Gastroesophageal Tumors. Gee, Denise W.; Rattner, David W. // Oncologist;Feb2007, Vol. 12 Issue 2, p175 

    The incidence of adenocarcinomas of the gastroesophageal junction has increased in recent years. These tumors possess distinct pathophysiologic characteristics. Although the consensus is that an R0 resection (complete microscopic and macroscopic resection) is the goal when operating for curative...

  • The Value of ap-Valueless Paper. Connor, Jason T. // American Journal of Gastroenterology;Sep2004, Vol. 99 Issue 9, p1638 

    As is common in current biomedical research, about 85% of original contributions inThe American Journal of Gastroenterologyin 2004 have reportedp-values. However, none are reported in this issue's article by Abrahamet al.who, instead, rely exclusively on effect size estimates and associated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics